Atherosclerosis and restenosis: Is there a role for RAGE?

Current Diabetes Reports

Volumn 5, Issue 1, 2005, Pages 11-16

  Nawroth, Peter ^b   Bierhaus, Angelika ^b   Marrero, Mario ^b   Yamamoto, Hiroshi ^b   Stern, David M ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BETA2 INTEGRIN; CELL SURFACE RECEPTOR; CHOLESTEROL; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE C BETA; PROTEIN S 100; RAS PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHO KINASE; SMAD PROTEIN; STAT PROTEIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROSIS; CELL ACTIVATION; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DISEASE ASSOCIATION; DISEASE EXACERBATION; HUMAN; HYPERLIPIDEMIA; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATTERN RECOGNITION; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; RESTENOSIS; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

EID: 14044268796     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-005-0061-9     Document Type: Review

References (54)

1. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; National Heart, Lung and Blood Institute; Juvenile Diabetes Foundation International; National Institute of Diabetes and Digestive and Kidney Diseases; and the American Heart Association [no authors listed]. Circulation 1999, 100:1132-1133.
2. Kannel W: Lipids, diabetes, and coronary heart disease: insights from the Framingham study. Am Heart J 1985, 110: 100-1107.
3. Stamler J, Vaccaro O, Neaton J, Wentworth D: Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 2003, 16:434-444.
4. Beckman J, Craeger M, Libby P: Diabetes and atherosclerosis. Epidemiology, pathophysiology and management. JAMA 2002, 287:2570-2581.
5. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352: 37-853.
6. Stratton I, Adler A, Neil H, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
7. Kastrati A, Schomig A, Elezi S, et al.: Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997, 30:1428-1436.
8. Mazeika P, Prasad N, Bui S, Seidelin P: Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J 2003, 145:1013-1021.
9. Kornowski R, Mintz G, Kent K, et al.: Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. Circulation 1997, 95: 366-1369.
10. Takagi T, Yamamuor A, Tamita K, et al.: Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003, 146:E5.
11. Phillips J, Barringhaus K, Sander J, et al.: Rosiglitazone reduces accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes. Circulation 2003, 108:1994-1999.
12. Schmidt AM., Vianna M, Gerlach M, et al.: Isolation and characterization of binding proteins for advanced glycosylation end products from lung tissue which are present on the endothelial cell surface. J Biol Chem 1992, 267:14987-14997.
13. Neeper M, Schmidt AM, Brett J, et al.: Cloning and expression of RAGE: a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992, 267: 4998-15004.
14. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1996, 47:223-234.
15. Kislinger T, Fu C, Huber B, et al.: N(epsilon) (carboxymethyl)lysine adducts of proteins are ligands for RAGE that activate cell signalling pathways and modulate gene expression. J Biol Chem 1999, 274:31740-31749.
16. Thornalley P: Cell activation by glycated proteins: AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy-le-grand) 1998, 44:1013-1023.
17. Hofmann M, Drury S, Caifeng F, et al.: RAGE mediates a novel proinflammatory axis: the cell surface receptor for S100/calgranulin polypeptides. Cell 1999, 7:889-901.
18. Hori O, Brett J, Slattery T, et al.: The receptor for advanced glycation endproducts (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J Biol Chem 1995, 270:25752-25761.
19. Chavakis T, Bierhaus A, Al-Fakhri N, et al.: The patter recognition receptor RAGE is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003, 198:1507-1515.
20. Yan SD, Chen X, Fu J, et al.: RAGE in Alzheimer's disease: a receptor mediating amyloid-beta peptide-induced oxidant stress and neurotoxicity and microglial activation. Nature 1996, 382:685-691.
21. Roth J, Vogl T, Sorg C, Sunderkotter C: Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol 2003, 24:155-158.
22. Wang H, Bloom O, Zhang M, et al.: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285: 48-251.
23. Sipe J: Amyloidosis. Annu Rev Biochem 1992, 61:947-975.
24. Deane R, Yan SD, Submamaryan RK, et al.: RAGE mediates amyloid-beta peptide transport across the blood-brain, suppression of cerebral blood flow and development of cerebral amyloidosis. Nat Med 2003, 9:907-913.
25. Arancio O, Zhang HP, Chen X, et al.: RACE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 2004, 23:4096-4105.
26. Schmidt AM, Yan SD, Yan SF, Stern D: RAGE: a multiligand receptor serving as a progression factor amplifying the immune/inflammatory response. J Clin Invest 2001, 108: 49-955.
27. Bouma B, Kroon-Batenburg L, Wu YP, et al.: Glycation induces formation of amyloid cross-beta structure in albumin. J Biol Chem 2003, 278:41810-41819.
28. Ishihara K, Tsutusmi K, Kawane S, et al.: RAGE directly binds to ERK by a D-domain-like docking site. FEBS Lett 2003, 550:107-113.
29. Brizzi M, Dentelli P, Rosso A, et al.: RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and p21waf to control cell-cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy. FASEB J 2004, 18:1249-1251.
30. Shaw SS, Schmidt AM, Banes AK, et al.: S100B-RAGE-mediated augmentation of angiotensin ii-induced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2. Diabetes 2003, 52:2381-2388.
31. Li J, Huang X, Zhu H, et al.: AGEs activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J 2004, 18: 76-178.
32. Huttumen J, Kuja-Panula J, Rauvala H: RAGE signaling induces CREB-dependent chromogranin expression during neuronal differentiation. J Biol Chem 2002, 277:38635-38646.
33. Huttunen H, Fages C, Rauvala H: RAGE-mediate neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999, 274:19919-19924.
34. Wautier MP, Chappey O, Corda S, et al.: Activation of NADPH oxidase by AGEs links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001, 280: 685-E694.
35. Wells-Knecht K, Zyzak D, Litchfield J, et al.: Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 1995, 21:3702-3709.
36. Nagai R, Ikeda K, Highashi T, et al.: Hydroxyl radical mediates N-epsilon-(carboxymethyl)lysine formation from Amadori product. Biochem Biophys Res Commun 1997, 234:167-172.
37. Fu M, Requena J, Jenkins A, et al.: The AGE, N-epsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996, 271: 982-9986.
38. Nagai R, Unno Y, Hayashi M, et al.: Peroxynitrite induces formation of N(epsilon)-(carboxymethyl)lysine by the cleavage of Amadori product and generation of glucosone and glyoxal from glucose: novel pathways for protein modification by peroxynitrite. Diabetes 2002, 51:2833-2839.
39. Anderson M, Requena, J, Crowley J, et al.: The myeloperoxidase system of human phagocytes generates N-epsilon-(carboxymethyl)lysine on proteins: a mechanism for producing AGEs at sites of inflammation. J Clin Invest 1999, 104: 03-113.
40. Schalkwijk C, Baidoshvili A, Stehouwer C, et al.: Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in hearts of diabetic patients; generation and characterization of a monoclonal anti-CML antibody. Biochim Biophys Acta 2004, 1636:82-89.
41. Nerlich A, Schleicher E: N-epsilon-(carboxymethyl)lysine in atherosclerotic vascular lesions as a marker for local oxidative stress. Atherosclerosis 1999, 144:41-47.
42. Park L, Raman K, Lee K, et al.: Suppression of accelerated diabetic atherosclerosis by soluble receptor for AGE (sRAGE) Nat Med 1998, 4:1025-1031.
43. Wautier JL, Zoukourian C, Chappey O, et al.: Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble receptor for advanced glycation end products blocks hyperpermeability. J Clin Invest 1996, 97:238-243.
44. Kislinger T, Tanji N, Wendt T, et al.: Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in the vasculature of diabetic apolipoprotein E null mice. Arterioscler Thromb Vasc Biol 2001, 21: 05-910.
45. Bucciarelli LG, Wendt T, Qu W, et al.: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002, 106:2827-2835.
46. Moreno P, Fallon J, Murcia A, et al.: Tissue characteristics of restenosis after percutaneous transluminal coronary angioplasty in diabetic patients. J Am Coll Cardiol 1999, 34: 045-1049.
47. Sakaguchi T, Yan SF, Yan SD, et al.: Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003, 111:959-972.
48. Seki Y, Kai H, Shibata R, et al.: Role of the JAK/STAT pathway in rat carotid artery remodeling after vascular injury Circ Res 2000, 87:12-18.
49. Zhou A, Wang K, Penn MS, et al.: Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 2003, 107:2238-2243.
50. Liliensiek B, Weigand MA, Bierhaus A, et al.: Receptor for advanced glycation end products (RAGE) regulating sepsis but not the adaptive immune response. J Clin Invest 2004, 113: 641-1650.
51. Park J, Svetkauskaite D, He Q, et al.: Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Bio Chem 2004, 279:7370-7377.
52. Fujita T, Asai T, Andrassy M, et al.: PKCbeta regulates ischemia/reperfusion injury in the lung. J Clin Invest 2004, 113:1615-1623.
53. Yan SF, Fujita T, Lu J, et al.: EGR-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 2000, 6:1355-1361.
54. Yan SF, Lu J, Zou YS, et al.: Protein kinase C-beta and oxygen deprivation: a novel Egr-1-dependent pathway for fibrin deposition in hypoxemic vasculature. J Biol Chem 2000, 275: 1921-11928.